Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/28/2025 | $24.00 → $15.00 | Overweight → Equal Weight | Wells Fargo |
| 12/11/2024 | $24.00 → $22.00 | Buy → Neutral | Citigroup |
| 12/2/2024 | $19.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/15/2024 | $19.00 → $25.00 | In-line → Outperform | Evercore ISI |
| 7/10/2024 | $19.00 | Outperform | Raymond James |
| 5/6/2024 | $16.00 → $18.00 | Equal-Weight → Overweight | Morgan Stanley |
| 1/4/2024 | $19.00 → $17.00 | Outperform → In-line | Evercore ISI |
| 12/12/2023 | $16.00 | Hold | Stifel |
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 30, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, April 30, 2025 Time: 8 a.m. ET Webcast: https://www.webcaster4.com/Webcast/Page/2883/51713 Participant Event Dial-in: +
Fourth-Quarter 2024 Financial Results Revenue of $1.280 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $3 Million Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $259 Million Revenue Grew 9% as Reported and 11% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2023, with Growth Across All Segments Full-Year 2024 Financial Results Revenue of $4.791 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $317 Million Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $878 Million Revenue Grew 16% as Reported and 17% on a Constant Currency1 Basis Compared to the Full Year of 2023, with Growth Across All Segments Baus
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2024 financial results on Wednesday, February 19, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, February 19, 2025 Time: 8 a.m. ET Webcast: https://www.webcaster4.com/Webcast/Page/2883/51712 Partici
SC 13G - Bausch & Lomb Corp (0001860742) (Subject)
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has identified the event that led to its recent voluntary recall of intraocular lenses (IOLs) on the enVista platform. Now that the cause and affected lots have been confirmed, the company will return these models to market. "We voluntarily recalled these lenses because patient safety dictates every decision we make," said Brent Saunders, chairman and CEO, Bausch + Lomb. "We wouldn't bring them back without full confidence in the enVista safety profile, which has been established over years and hundreds of thousands of implants." Investig
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE Recycling and Biotrue Eye Care Recycling programs have collected a total of 103,169,500 units, or 625,026 pounds, of used contact lenses, eye care and lens care materials in the United States. That's equivalent to the weight of approximately 600 concert grand pianos1. "These award-winning recycling programs continue to drive a positive environmental impact, offering eye care professionals, patients and consumers a way to properly recycle used eye health materials," said Amy Butler, Vice President, Global Environment,
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced a voluntary recall of intraocular lenses (IOLs) on its enVista platform. This action was taken out of an abundance of caution after the company received reports of complications, the cause of which could not immediately be explained. "As much as we believe in the enVista platform, patient safety will always be our number one priority," said Brent Saunders, chairman and CEO, Bausch + Lomb. "Surgeons and patients trust Bausch + Lomb, and I believe that this voluntary recall is the best thing we can do to honor that trust." The recall is in res
DEF 14A - Bausch & Lomb Corp (0001860742) (Filer)
10-K - Bausch & Lomb Corp (0001860742) (Filer)
8-K - Bausch & Lomb Corp (0001860742) (Filer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
Wells Fargo downgraded Bausch + Lomb from Overweight to Equal Weight and set a new price target of $15.00 from $24.00 previously
Citigroup downgraded Bausch + Lomb from Buy to Neutral and set a new price target of $22.00 from $24.00 previously
Morgan Stanley downgraded Bausch + Lomb from Overweight to Equal-Weight and set a new price target of $19.00
Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,
Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai
Mr. Bailey and Mr. Stewart Will Join Bausch + Lomb on April 24, 2023 Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, announced the appointments of Bob Bailey as executive vice president (EVP) and Chief Legal Officer and Andrew Stewart as president, Ophthalmic Pharmaceuticals, effective April 24, 2023. Both Mr. Bailey and Mr. Stewart will join the executive management team of the Company. Concurrent with these appointments, Christina Ackermann will step down from her role as EVP, General Counsel and president, Ophthalmic Pharmaceuticals, and will leave Bausch + Lomb on April